SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Applied Digital Corp. is a technology company, which engages in the provision of development and operation of data centers which provide computing power. It operates through the Data Center Hosting Business and HPC Hosting Business segments. The Data Center Hosting Business segment provides energized infrastructure services to crypto mining customers. The HPC Hosting Business segment focuses on the designing, constructing, and operating data centers tailored to support high power density applications like HPC and AI. The company was founded by Wesley Carl Cummins and Jason Zhang in May 2001 and is headquartered in Dallas, TX.

Applied Digital Corporation

Applied Digital is trending as investors vigorously debate NVIDIA's recent exit from its APLD stake, with some viewing it as strategic profit-taking for an AI infrastructure provider that has matured, while others interpret it as a concerning signal about its future prospects.

Rolls-Royce Holdings Plc designs, develops, manufactures, and services integrated power systems for use in the air, on land, and at sea. The company operates its business through following segments: Civil Aerospace, Power Systems, Defense and New Markets. The Civil Aerospace segment offers commercial aero engines and aftermarket services. The Power Systems segment includes engines, power systems and nuclear systems for civil power generation. The Defense segment consists of military aero engines, naval engines, submarines and aftermarket services. The New Markets segment includes development, manufacture and sales of small modular reactors (SMRs) and new electrical power solutions. The company was founded in March 1906 and is headquartered in London, the United Kingdom.

Rolls-Royce Holdings Plc - ADR

Rolls-Royce Holding PLC (ADR)

Rolls-Royce Holdings is trending as a key beneficiary of global rearmament and surging civil aerospace demand, highlighted by a significant engine order from Delta Air Lines and numerous defense contracts. The community anticipates strong upcoming earnings, fueled by these catalysts and long-term optimism for its small modular reactor (SMR) and power systems solutions for data centers.

United States Antimony Corp. engages in the extraction, processing and sale of antimony, zeolite, silver, and gold products. It operates through the following segments: United States Antimony Operations, Mexican Antimony Operations, Precious Metals Recovery, and United States Zeolite Operations. The company was founded by John C. Lawrence in June 1968 and is headquartered in Thompson Falls, MT.

United States Antimony Corp.

United States Antimony Corp

United States Antimony is trending following a landmark joint venture with Americas Gold and Silver to establish North America's first commercial hydrometallurgical processing facility for critical minerals, a move seen as vital for strengthening domestic supply chains. The community, however, is actively discussing widespread frustration over the stock's price action, attributing it to persistent market manipulation despite the overwhelmingly positive news and analyst upgrades.

Palo Alto Networks, Inc. engages in the provision of network security solutions to enterprises, service providers, and government entities. It operates through the following geographical segments: the United States, Israel, and Other Countries. The company was founded by Nir Zuk in March 2005 and is headquartered in Santa Clara, CA.

Palo Alto Networks Inc

Palo Alto Networks is trending following its latest earnings report, which, despite beating revenue and EPS, saw future profit guidance trimmed and analyst price targets cut, triggering a sharp sell-off. The community is fiercely debating whether this decline is an overreaction driven by broader 'AI panic' and M&A integration costs, or a justified repricing for an overvalued stock with concerns over declining margins.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is a focal point for investors anticipating the imminent BLA resubmission for its Duchenne Muscular Dystrophy therapy, Deramiocel, driven by robust Phase 3 data and increasing institutional ownership, alongside excitement for its promising exosome platform.

Atomera, Inc. engages in the development, commercialization, and licensing of proprietary processes and technologies for the semiconductor industry. It developed Mears Silicon Technology, which increases performance and power efficiency in semiconductor transistors. The company was founded by Robert Mears on November 26, 2001 and is headquartered in Los Gatos, CA.

Atomera Inc

Atomera Inc. is trending with significant trading volume as its recent earnings call highlighted optimism for MST technology addressing critical power efficiency in AI chips and Gate-All-Around architectures, fueling widespread community discussion about potential commercial agreements with major foundries.

Quantum Resistant Ledger is a cryptocurrency based on the Python programming language, aimed at combating future attacks by quantum computers. This cryptocurrency is the brainchild of Peter Waterland who realised that Bitcoin, Ethereum, and other such cryptocurrencies have no protection against future technology. It claims to be a “future-proof” cryptocurrency which enables transactions and decentralized communication while providing protection against classical as well as quantum computer attacks.  The Quantum Resistant Ledger company was founded by Peter Waterland, who found that Bitcoin, as well as Ethereum signatures are susceptible to attacks by powerful quantum computers. His research on quantum computers and signature programs let to the development of this new cryptocurrency, designed to be resistant to the present classical attacks as well as any future quantum computer attacks. Their team is made up of a diverse range of members spread out across the world, including developers (core, blockchain, mobile developers, etc.), analysts, advisors, marketing managers, designers and more.  Quantum Resistant Ledger is the first ever cryptocurrency and the only one in existence as of August 2018, to consider the threat that the future technology of quantum computing poses to cryptocurrencies and their working. It uses a technology specifically designed for post-quantum security, called XMSS, which makes it secure against powerful quantum computers even while using a Proof-of-Stake consensus mechanism. Security against cyber-attacks is a very serious concern in this digital age, especially when you have digital assets whose loss is likely to lead you to bankruptcy.  QRL is the first blockchain technology that provides durability and stability through resistance to quantum computer attacks. The encryption methods used by modern blockchains can become vulnerable to quantum computers over the next ten years. QRL tries to create a blockchain with long-term stability. By using blockchain technology, the QRL platform creates a “ledger” that generates hashes in such a way that it is virtually impenetrable to any type of computer attack.

Quantum Resistant Ledger 

Quantum Resistant Ledger (QRL) is trending as accelerating quantum computing advancements fuel growing market concerns over the future security of traditional cryptocurrencies, positioning QRL as a vital quantum-resistant hedge. The community is actively discussing QRL's upcoming 2.0 upgrade to introduce post-quantum smart contracts, alongside recent platform listings and OTC service availability, as key catalysts for its role in securing digital assets against emerging quantum threats.

WorldFinancial

WLFI is highly contentious amid an anticipated Mar-a-Lago event with institutional players, where the community debates potential institutional adoption against ongoing congressional scrutiny and a probe into its foreign investment and governance.

BRC Group Holdings, Inc. engages in the provision of financial services and solutions to the capital raising and financial advisory needs of public and private firms. It operates through the following segments: Capital Markets, Wealth Management, Financial Consulting, Auction and Liquidation, Communications, and Consumer. The Capital Markets segment provides investment banking, corporate finance, research, wealth management, and sales and trading services to corporate, institutional, and high net worth clients. The Wealth Management segment offers retail brokerage, investment management, and insurance, and tax preparation services. The Financial Consulting segment focuses on a variety of specialized advisory services spanning bankruptcy, restructuring, turnaround management, forensic accounting, crisis and litigation support, appraisal and valuation, real estate, and operations management. The Auction and Liquidation segment deals with retail liquidation services. The Communications segment is composed of a portfolio of companies acquired for attractive risk-adjusted investment return characteristics. The Consumer segment includes Targus and the Brands investment portfolio. The company was founded in 1973 and is headquartered in Los Angeles, CA.

BRC Group Holdings Inc.

B. Riley Financial Inc

B. Riley Financial is trending as it recently regained NASDAQ compliance and reported strong preliminary Q4 results, reinforcing its turnaround narrative and addressing solvency concerns. Community discussion highlights the stock's deep undervaluation and high short interest, with many expressing frustration over perceived manipulation and low volume despite significant asset appreciation in its BW and APLD holdings.

Compass Pathways Plc is a biotechnology company, which provides mental health care services. It focuses on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. The company was founded by Goldsmith George Jay and Malievskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

Compass Pathways Plc - ADR

COMPASS Pathways

COMPASS Pathways is experiencing a significant surge and high volume following successful Phase 3 trial results for its COMP360 psilocybin therapy in treatment-resistant depression, demonstrating strong efficacy and a favorable safety profile. The community is actively discussing the potential for this to be the first FDA-approved psilocybin medicine, though a recent public offering is also a point of conversation regarding dilution.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Agenus to Present New Data at AACR-IO Exploring Systemic and Tumor Inflammation Biomarkers with BOT/BAL in Immunologically Cold Tumors

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced that new translational and clinical biomarker analyses from its botensilimab (BOT) immunotherapy program have been accepted...

Agenus Inc. (NASDAQ:AGEN) Given Consensus Recommendation of "Hold" by Brokerages

Agenus Inc. (NASDAQ:AGEN - Get Free Report) has earned an average recommendation of "Hold" from the five analysts that are currently covering the company, MarketBeat Ratings reports. One analyst has...

Agenus Webcast: Zydus Manufacturing Deal Closes, France Access Expands, Phase 3 BATMAN Nears Launch

Agenus (NASDAQ:AGEN) used its first 2026 stakeholder webcast to outline operational and clinical priorities tied to its botensilimab/balstilimab (BOT/BAL) immunotherapy program, highlighting a...

Agenus Expands Medical Affairs Infrastructure to Support Increasing Physician Requests for Authorized Access to Botensilimab Plus Balstilimab

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the expansion of its global Medical Affairs infrastructure and early-access support capabilities in response to...

Agenus to Host First 2026 Stakeholder Webcast

Agenus Inc. (Agenus) (Nasdaq: AGEN), a leader in immuno-oncology, today announced it will host its first Stakeholder Webcast of 2026, Access to Acceleration: Agenus Global Momentum Entering 2026 on...

Agenus Inc. (NASDAQ:AGEN) Sees Significant Increase in Short Interest

Agenus Inc. (NASDAQ:AGEN - Get Free Report) was the target of a large increase in short interest in December. As of December 31st, there was short interest totaling 3,399,217 shares, an increase of...

FY2030 Earnings Estimate for Agenus Issued By HC Wainwright

Agenus Inc. (NASDAQ:AGEN - Free Report) - HC Wainwright issued their FY2030 earnings estimates for shares of Agenus in a research note issued on Thursday, January 15th. HC Wainwright analyst E...

Zydus Lifesciences Limited completes the acquisition of Agenus Inc.'s biologics manufacturing facilities, launches Zylidac Bio LLC in the U.S.

Zydus Lifesciences Limited completes the acquisition of Agenus Inc.'s biologics manufacturing facilities, launches Zylidac Bio LLC in the U.S. Zydus Lifesciences Limited completes the acquisition of...

Agenus Announces Closing of $141M Strategic Collaboration with Zydus Lifesciences to Advance BOT+BAL and Strengthen U.S. Manufacturing Readiness

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the closing of its previously disclosed strategic collaboration with Zydus Lifesciences Ltd. The agreement is...

Agenus (AGEN) Upgraded to Buy: What Does It Mean for the Stock?

Agenus (AGEN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Agenus, Inc. is a clinical-stage company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes Balstilimab, Zalifrelimab, AGEN1181, AGEN1327, AGEN2373, AGENt-797 and AGEN1777. The company was founded by Garo H. Armen and Pramod K. Srivastava on March 31, 1994 and is headquartered in Lexington, MA.

Agenus Inc

Fundamental

Technical

A mix of both

Some investors focus on company fundamentals like earnings, growth, and valuation. Others rely on price action, trends, and momentum. Many use a combination of both to guide their decisions. What do you use?

What type of analysis drives your investment decisions?

Current Price	$3.05
Prev Close	$2.92
Open	$2.92
Dividend Yield	0.00%
50-Day Moving Average	$3.45
Beta	1.91
Avg. Volume	924,762.35
PE Ratio	-1.37

52-Week High	$7.34
52-Week Low	$1.38
Market Capitalization	$99.3M
EPS (Annual)	-$10.59
Price to Book	-0.35
Revenue Per Employee	$327,414.56

AGEN
Agenus Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest AGEN News

AGENAgenus Inc